<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810182</url>
  </required_header>
  <id_info>
    <org_study_id>IOV-GB-1-2020 REGOMA-OSS</org_study_id>
    <nct_id>NCT04810182</nct_id>
  </id_info>
  <brief_title>Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS</brief_title>
  <official_title>Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the role the of Regorafenib in prolonging the Overall Survival of&#xD;
      glioblastoma multiforme patients who progressed after surgery and a first-line&#xD;
      chemo-radiotherapy treatment in the setting of &quot;real world life&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the enrolment date to the date of death, for any cause, or to the last follow-up, assessed up to 18 months</time_frame>
    <description>Overall Survival is defined as the time from date of enrolment to the date of death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From the date of enrolment to the date of disease progression or to the date of death, assessed up to 18 months</time_frame>
    <description>from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As percentage of patients achieving a complete response plus partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As percentage of patients achieving a complete response plus partial response plus stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events-CTCAE v5.0)</measure>
    <time_frame>From the start of Regorafenib treatment up to 30 days after the end of treatment</time_frame>
    <description>Toxicity during the treatment will be recorded and graded according to the NCICommon Terminology Criteria for Adverse Events (CTCAE) v.4.. , related to severity of the adverse event from Grade 1 to Grade 5</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Glioblastoma Patients treated with Regorafenib</arm_group_label>
    <description>Patients with a confirmed diagnosis of Glioblastoma for whom a decision to treat with regorafenib has been made (by the treating physician).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib 40 MG Oral Tablet [STIVARGA]</intervention_name>
    <description>As per the treating physicians discretion</description>
    <arm_group_label>Glioblastoma Patients treated with Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapse of glioblastoma (grade IV) after surgery and radio-chemotherapy first&#xD;
        line treatment, treated with Regorafenib until disease progression or the appearance of&#xD;
        unacceptable toxicity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  Histologically confirmed glioblastoma (grade IV)&#xD;
&#xD;
          -  First recurrence after adjuvant treatment (surgery followed by radiotherapy and&#xD;
             temozolomide chemotherapy) in patients who have not received further therapeutic&#xD;
             interventions&#xD;
&#xD;
          -  World Health Organization (WHO) Performance status ≤ 1 (or Karnofsky performance&#xD;
             status (KPS) ≥70)) before the start of the treatment&#xD;
&#xD;
          -  Documented progression of disease as defined by RANO criteria at least 12 weeks after&#xD;
             completion of radiotherapy, unless the recurrence is outside the radiation field or&#xD;
             has been histologically documented.&#xD;
&#xD;
          -  Documented progression of disease by a brain MRI scan done within 14 days before the&#xD;
             start of treatment with Regorafenib.&#xD;
&#xD;
          -  Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.&#xD;
&#xD;
          -  Have adequate bone marrow function, liver function, and renal function, as measured by&#xD;
             the following laboratory assessments conducted within 7 days prior to the initiation&#xD;
             of study treatment:&#xD;
&#xD;
          -  Hemoglobin &gt;9.0 g/dl&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;1500/mm3 without transfusions or granulocyte colony&#xD;
             stimulating factor and other hematopoietic growth factors&#xD;
&#xD;
          -  Platelet count ≥100,000/μl&#xD;
&#xD;
          -  White blood cell count (WBC) &gt;3.0 x 109/L&#xD;
&#xD;
          -  Total bilirubin &lt;1.5 times the upper limit of normal&#xD;
&#xD;
          -  ALT and AST &lt;3 x upper limit of normal&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 x upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt;2.5 x ULN (&lt;5 x upper limit of normal value)&#xD;
&#xD;
          -  PT-INR/PTT &lt;1.5 x upper limit of normal&#xD;
&#xD;
          -  Lipase ≤ 1.5 x the ULN&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 30 mL/min/1.73 m2&#xD;
&#xD;
          -  TSH, fT3,fT4 within normal limits&#xD;
&#xD;
          -  Patients may have undergone surgery for the recurrence; the histological report must&#xD;
             document a glioblastoma recurrence. If operated:&#xD;
&#xD;
          -  at least 28 days from the surgery is required prior to Regorafenib administration and&#xD;
             patients should have fully recovered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had prior treatment with regorafenib or any other VEGFR-targeting kinase&#xD;
             inhibitor&#xD;
&#xD;
          -  Have had systemic anticancer therapy including cytotoxic therapy, signal transduction&#xD;
             inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation&#xD;
             of treatment&#xD;
&#xD;
          -  Recurrent disease located outside of the brain&#xD;
&#xD;
          -  Have uncontrolled hypertension (systolic blood pressure [SBP] &gt; 140 mmHg or diastolic&#xD;
             blood pressure [DBP] &gt; 90 mmHg) despite optimal medical management&#xD;
&#xD;
          -  Have had a myocardial infarction &lt; 6 months prior to initiation of treatment with&#xD;
             Regorafenib&#xD;
&#xD;
          -  Have had arterial thrombotic or embolic events such as cerebrovascular accident&#xD;
             (including transient ischemic attacks), or pulmonary embolism within 6 months prior to&#xD;
             the initiation of treatment with Regorafenib&#xD;
&#xD;
          -  Have either active or chronic hepatitis B or C requiring treatment with antiviral&#xD;
             therapy&#xD;
&#xD;
          -  Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir,&#xD;
             itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir,&#xD;
             saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine,&#xD;
             phenobarbital, phenytoin, rifampin, St. John's Wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Generale Regionale &quot; F.Miulli &quot;</name>
      <address>
        <city>Acquaviva Delle Fonti</city>
        <state>BA</state>
        <zip>70021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabiana Gregucci</last_name>
      <phone>0803054608</phone>
      <email>fabianagregucci@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Stucci</last_name>
      <phone>080 5592673</phone>
      <email>stefania.stucci@uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Saverio de Bellis&quot;</name>
      <address>
        <city>Castellana Grotte</city>
        <state>BA</state>
        <zip>70013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivan Lolli</last_name>
      <email>ivanlolli53@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedlae S. Martino</name>
      <address>
        <city>Belluno</city>
        <state>BL</state>
        <zip>32100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fable Zustovich</last_name>
      <phone>3479774774</phone>
      <email>fable.zustovich@aulss1.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Franceschi</last_name>
      <phone>051-6225697</phone>
      <email>e.franceschi@ausl.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Perrino</name>
      <address>
        <city>Brindisi</city>
        <state>BR</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Cinieri</last_name>
      <phone>0831537431</phone>
      <email>saverio.cinieri@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università e ASST Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Buglione di Monale</last_name>
      <phone>347-6150805</phone>
      <email>michela.buglione@unibs.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irst-Irccs</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Ibrahim</last_name>
      <phone>05437391</phone>
      <email>toni.ibrahim@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria Annunziata</name>
      <address>
        <city>Bagno A Ripoli</city>
        <state>FI</state>
        <zip>50012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Scoccianti</last_name>
      <phone>055-69366729</phone>
      <email>silvia.scoccianti@uslcentro.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Livi</last_name>
      <phone>0557947264</phone>
      <email>lorenzo.livi@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Livorno</name>
      <address>
        <city>Livorno</city>
        <state>LO</state>
        <zip>57100 -</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Stasi</last_name>
      <phone>3396892795</phone>
      <email>irene.stasi@uslnordovest.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Provinciale</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Santoni</last_name>
      <phone>0733 2572553</phone>
      <email>matteo.santoni@sanita.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico &quot;G.Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Carmela Santarpia</last_name>
      <phone>0902217002</phone>
      <email>msantarpia@unime.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico C. Besta IRCCS</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poala Gaviani</last_name>
      <phone>0223942440</phone>
      <email>paola.gaviani@istiuto-besta.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Simonelli</last_name>
      <phone>0282244559</phone>
      <email>matteo.simonelli@hunimed.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale del Mare</name>
      <address>
        <city>Napoli</city>
        <state>NL</state>
        <zip>80145</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pasqualina Giordano</last_name>
      <phone>081 18775337</phone>
      <email>giopas@email.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Istiuto Giglio Cefalù</name>
      <address>
        <city>Cefalù</city>
        <state>PA</state>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianfranco Pernice</last_name>
      <phone>0921-920302</phone>
      <email>gianfranco.pernice@hsrgiglio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aulss6 Euganea Padova Sud Ospedali Riuniti</name>
      <address>
        <city>Piove Di Sacco</city>
        <state>PD</state>
        <zip>35131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Chiari</last_name>
      <phone>0429715535</phone>
      <email>rita.chiari@aulss6.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Pisa</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabiola Paiar</last_name>
      <phone>050 993541</phone>
      <email>fabiola.paiar@unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena -IFO</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Villani</last_name>
      <phone>065291103</phone>
      <email>veronica.villani@ifo.gov.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Chiesa</last_name>
      <phone>06 30155226</phone>
      <email>silvia.chiesa@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rovigo</name>
      <address>
        <city>Rovigo</city>
        <state>RO</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Stievano</last_name>
      <phone>0429 39446</phone>
      <email>laura.stievano@aulss5.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Siena</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Minniti</last_name>
      <phone>0577 585411</phone>
      <email>giuseppe.minniti@unisi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria della Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Franchino</last_name>
      <phone>011 6334904</phone>
      <email>fedef8@virgilio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Caserta</last_name>
      <phone>0744205631</phone>
      <email>caserta_claudia@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donà di Piave _Azienda ULSS 4 &quot; Veneto Orientale&quot;</name>
      <address>
        <city>San Dona di Piave</city>
        <state>VE</state>
        <zip>30027</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Zanon</last_name>
      <phone>0421/227288</phone>
      <email>silvia.zanon@aulss4.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AULSS 7 Distretto 2 Ospedale Santorso</name>
      <address>
        <city>Santorso</city>
        <state>VI</state>
        <zip>36014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliviero Puccetti</last_name>
      <phone>0445 571244</phone>
      <email>oliviero.puccetti@aulss7.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AULSS 9 Scaligera Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <state>VR</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bonetti</last_name>
      <phone>0442 622801</phone>
      <email>oncologia.medica.leg@aulss9.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Friuli Centrale</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Rizzato</last_name>
      <phone>0432- 559330</phone>
      <email>simona.rizzato@asufc.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

